Originally published Tuesday, August 5, 2008 at 12:00 AM
Bothell biotech laying off 30 percent of employees
MDRNA is axing 20 employees — plus its three top executives — as it shifts its focus from intranasal drug treatments toward therapies based on RNA interference, a promising but still undeveloped sector in biotechnology.
Seattle Times business reporter
MDRNA said Monday it would lay off nearly 30 percent of its work force, including three top executives, as it seeks to recover from failed late-stage clinical trials by transforming itself into a leaner, discovery-focused biotechnology company.
The Bothell firm, formerly known as Nastech Pharmaceuticals, said it would let go 23 employees, mostly involved with its intranasal-therapeutics programs. Most of the laid-off employees will leave before the end of August.
Company President Gordon Brandt, chief scientific officer for intranasal delivery Henry Costantino and chief business officer Timothy Duffy will go by Sept. 30, according to a statement filed with federal securities regulators.
The changes come as the company shifts its focus from intranasal-drug treatments toward therapies based on RNA interference, a promising but still undeveloped sector in biotechnology.
During an earnings call Monday, the company said it would try to license most of its relatively advanced intranasal programs even as it unveiled a broad pipeline of RNAi-based therapies that are still at an early stage of research.
RNAi therapies seek to treat disease by switching off certain genes that cause problems.
Most of these programs focus on cancer, metabolic disorders and inflammatory diseases. There's also a research program for an influenza drug, and the company is looking for a partner to start early-stage studies in humans for that product.
It also expects to get a cholesterol-busting treatment into human trials by the end of next year.
After the layoffs, the company will have about 55 full-time employees, down from 235 last October.
The transformation has been "pretty dramatic" and difficult for the corporate culture, said Michael French, recently appointed chief executive. But "we're focused on where the company is moving forward," added French, who comes from Sirna Therapeutics, an RNAi company Merck bought in late 2006 for $1.1 billion.
At the end of June, MDRNA had some $16.6 million in cash and cash equivalents. The company may require some capital by the end of the year, executives said Monday.
The company's management aims to get some cash by licensing its intranasal products or engaging in partnerships. "We feel very strongly that we've got enough to make it to key milestones in our program," said French.
![]()
MDRNA's struggles began when Procter & Gamble pulled out of a potentially lucrative research partnership with the company last November, after it determined a nasal spray for the treatment of osteoporosis wasn't working as well as expected.
The company said last week that its experimental nasal spray to treat obesity had failed at a midstage clinical trial.
MDRNA released the layoff news after the market closed. In regular trading, the stock lost 10 cents to close at $1.11. In the last year it has traded as high as $17.05 a share.
Ángel González: 206-515-5644 or agonzalez@seattletimes.com
| MDRNA's results | |||
| Dollar figures in thousands, except per share; parentheses denote losses. | |||
| June 30 | % | ||
| 2nd QTR | 2008 | 2007 | CHG |
| Profit | ($14,331) | ($12,367) | -15.9 |
| Per share | (0.48) | (0.50) | +4.0 |
| Revenue | 754 | 4,860 | -84.5 |
| 1st HALF | 2008 | 2007 | CHG |
| Profit | ($30,849) | ($23,907) | -22.5 |
| Per share | (1.10) | (0.97) | -13.4 |
| Revenue | 2,017 | 9,852 | -79.5 |
Copyright © 2008 The Seattle Times Company
An 802.11n upgrade could make a big difference
Retailers opening doors on Thanksgiving Day
Google makes concessions on digital book deal
Critics want to block Comcast-NBC deal
Google submits revised book settlement

Opening day at Crystal Mountain
Skiers crowded the slopes at Crystal Mountain for one of the resort's earliest openings.
nwjobs

Post a comment

Michelle Goodman blogs about work/life balance.
How to tell your office you're gravely ill
Post a comment
nwautos

Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment
- Homeless man, 46, arrested in Greenwood arsons
- KVI talk radio host off the air as of Thursday
- Steve Kelley | ESPN's Bill Simmons gets us: He hates Clay Bennett, too
- Police investigate videotaped arrest
- Seattle U. Men's Hoops | Big recruit goes from Huskies to Redhawks
- Mariners sign Jack Wilson to 2-year contract
- Razor found in muffin an accident, 'mortified' baker says
- Suspect's family shaken by slaying of police officer
- Mountlake Terrace woman reports razor in muffin
- Man says he will protest city's gun ban by carrying gun into community center
- OSU game thread
652 - Police investigate videotaped arrest
635 - Seattle man to pack a pistol into community center to protest mayor's ban
357 - GOP clueless as families struggle with health care
196 - NYC trial for 9/11 suspects poses risks
132 - Band of advocates, activists now McGinn's likely insiders
99 - Wright State game thread
97 - Licata looks at boosting traffic-ticket revenue
89 - Kent man challenges Seattle Mayor Greg Nickels' gun ban
88 - Light rail to airport to begin Dec. 19
71
- Light rail to airport to begin Dec. 19
- Homeless man, 46, arrested in Greenwood arsons
- Ivar's undersea billboards a hoax devised as marketing ploy
- Light rail to airport to begin Dec. 19
- Steve Kelley | ESPN's Bill Simmons gets us: He hates Clay Bennett, too
- An 802.11n upgrade could make a big difference
- KVI talk radio host off the air as of Thursday
- Washington in race for federal education funds
- Police investigate videotaped arrest
- Goodwill's Glitter Sale is Nov. 14-15





